Celyad SA Change in Assets/Liabilities 2014-2024 | CYAD

Celyad SA change in assets/liabilities from 2014 to 2024. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities

Celyad SA Change in Assets/Liabilities 2014-2024 | CYAD

Celyad SA change in assets/liabilities from 2014 to 2024. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$246.7B
Amgen (AMGN)$159.1B
Gilead Sciences (GILD)$146.4B
Vertex Pharmaceuticals (VRTX)$100.2B
Bristol Myers Squibb (BMY)$98.4B
GSK (GSK)$80.7B
CSL (CSLLY)$70.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Alnylam Pharmaceuticals (ALNY)$60.1B
Argenex SE (ARGX)$40.2B
Insmed (INSM)$26.9B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.7B
Illumina (ILMN)$15.6B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15.3B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.1B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.6B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.2B
Roivant Sciences (ROIV)$8B